目的 探讨复方血栓通胶囊联合非洛地平片治疗冠心病心绞痛的临床疗效。方法 选取河北省第八人民医院在2023年3月—2025年10月收治的冠心病心绞痛患者共计78例，所有患者运用随机数字表法分为对照组和治疗组，各包括39例。对照组口服非洛地平片，2次/d，初始剂量2.5 mg/次，持续1周后调整为5 mg/次。治疗组在对照组基础上口服复方血栓通胶囊，3粒/次，3次/d。两组持续治疗8周。对比两组临床疗效、症状改善时间、心绞痛疼痛程度、生活质量、心电图功能和血清指标。结果 完成疗程后，对照组的总有效率79.49%低于治疗组的总有效率94.87%，组间数据差异显著（P＜0.05）。治疗组患者胸痛、气短、乏力消失时间均短于对照组（P＜0.05）。治疗后，两组的视觉模拟法（VAS）评分明显降低，西雅图心绞痛调查表（SAQ）评分明显升高（P＜0.05）；治疗组治疗后的VAS评分低于对照组，SAQ评分高于对照组（P＜0.05）。两组治疗后的心电图总体标准差、均值标准差明显升高，缺血总负荷明显降低（P＜0.05）；治疗组治疗后的总体标准差、均值标准差高于对照组，缺血总负荷低于对照组（P＜0.05）。两组治疗后的血清γ-谷氨酰转移酶（GGT）、NADPH氧化酶4（NOX4）水平显著降低，血清可溶性晚期糖基化终末产物受体（sRAGE）、谷胱甘肽（GSH）水平显著升高（P＜0.05）；治疗组治疗后的血清GGT、NOX4水平低于对照组，血清sRAGE、GSH水平高于对照组（P＜0.05）。结论 复方血栓通胶囊联合非洛地平片可提高冠心病心绞痛的临床疗效，减轻临床症状、心绞痛严重程度和心肌缺血程度，降低氧化应激反应。

Objective To investigate the clinical efficacy of Compound Xueshuantong Capsules combined with Felodipine Tablets in treatment of coronary heart disease with angina pectoris. Methods A total of 78 patients with coronary heart disease and angina pectoris admitted to Hebei Provincial Eighth People’s Hospital from March 2023 to October 2025 were selected. All patients were divided into control group and treatment group using a random number table method, with 39 cases in each group. The control group was orally administered Felodipine Tablets at a dosage of 2.5 mg per time twice daily, and after one week, the dosage was adjusted to 5 mg per time. The treatment group received oral administration of Compound Xueshuantong Capsules based on the control group regimen, 3 capsules per time, three times daily. Two groups were treated for 8 weeks. The clinical efficacy, symptom improvement time, severity of angina pain, quality of life, electrocardiogram function, and serum indicators were compared between two groups. Results After completing the treatment course, the total effective rate (79.49%) of the control group was lower than 94.87% of the treatment group with significant difference between two groups (P < 0.05). The disappearance time of chest pain, shortness of breath, and fatigue in the treatment group was shorter than that in the control group (P < 0.05). After treatment, Visual Analog Scale (VAS) scores in two groups showed a significant decrease, but showed a significant increase in Seattle Angina Questionnaire (SAQ) scores (P < 0.05). The VAS scores of the treatment groups were lower than those of the control group after treatment, but the SAQ scores were higher than those of the control group (P < 0.05). After treatment, the overall standard deviation and mean standard deviation of electrocardiograms in two groups were significantly increased, but the total ischemic burdens were significantly decreased (P < 0.05). The overall standard deviation and mean standard deviation of the treatment group were higher than those of the control group after treatment, but the total ischemic burdens were lower than those of the control group (P < 0.05). After treatment, the serum levels of γ-glutamyltransferase (GGT) and NADPH oxidase 4 (NOX4) significantly decreased in two groups, while the serum levels of soluble advanced glycation end product receptor (sRAGE) and glutathione (GSH) significantly increased (P < 0.05). The serum levels of GGT and NOX4 in the treatment group were lower than those in the control group after treatment, while the serum levels of sRAGE and GSH were higher than those in the control group (P < 0.05). Conclusion The combination of Compound Xueshuantong Capsules and Felodipine Tablets can improve the clinical efficacy of coronary heart disease with angina pectoris, alleviate clinical symptoms, severity of angina pectoris and myocardial ischemia, and decrease oxidative stress response.

R972

河北省中医药管理局科研计划项目（2025305）